Products
Meloxicam was commercially available in tablet form (Mobicox). It was approved in many countries since 1995. It was discontinued from distribution in 2016.
Structure and properties
Meloxicam (C14H13N3O4S2, Mr = 351.4 g/mol) belongs to the oxicams and is a thiazole and a benzothiazine derivative. It exists as a yellow powder that is practically insoluble in water.
Effects
Meloxicam (ATC M01AC06) has analgesic, antipyretic, and anti-inflammatory properties. The effects are due to inhibition of the synthesis of prostaglandins via cyclooxygenase. Meloxicam is more selective for COX-2 than for COX-1 and has a long half-life of 13 to 25 hours.
Indications
For the treatment of pain and inflammatory conditions of various causes:
- Chronic polyarthritis
- Osteoarthritis
- Sciatica syndrome
- Ankylosing spondylitis
Dosage
According to the professional information. The tablets are usually taken once a day during a meal.
Contraindications
Numerous precautions must be observed when administering NSAIDs. Full details can be found in the drug label. Meloxicam is metabolized by CYP2C9.
Adverse effects
The most common potential adverse effects include digestive symptoms such as dyspepsia, nausea, vomiting, abdominal pain and diarrhea, and headache. As with other nonsteroidal anti-inflammatory drugs, serious side effects such as gastric and intestinal ulcers, cardiovascular disease, severe skin reactions, and kidney disease are possible.
